The Russian president thought he could outlast the opprobrium of the easily distracted West. It's a gamble he's lost
With few new buyers, the superjumbo's fate is up in the air
Instead of fighting for more regulations, they're pushing for market-based solutions
Vessel wants YouTube stars to focus on another platform
JPMorgan's chief helps kill a Dodd-Frank rule and does the heavy lifting for Wall Street
MetaMind customizes its deep-learning software for businesses that want to learn faster
The final installment of "Serial," a cult-favorite podcast about a murder, will begin just like every other episode—with the name of a prison telecom provider
"These colleges are ranked the top in the country, and it's surprising to me that they can't send out a simple email."
Customer service is one area where small businesses can beat big-box competitors
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."